$GSK

Global antibiotic resistance market to grow from $9.78B (2026) to $12.72B (2031) at 5.4% CAGR, driven by rising drug-resistant infections and antimicrobial innovation.

Delaware Chancery Court dismissed Tesaro's anticipatory breach claim against AnaptysBio, validating the biotech firm's contractual position ahead of July 2026 trial.

Omics clinical trials market grows 8.8% annually from $31.71B in 2025 to $47.78B by 2030, driven by personalized medicine demand and AI advances.

Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.

Clinical-stage biotech ENA Respiratory appoints Melissa Faris, GSK respiratory veteran, as independent director to strengthen governance during INNA-051 development.

SLE drug market projected to grow nearly 150% to $5.9B by 2034 on new therapies, but biosimilar competition and pricing pressure could limit upside.

Interstitial lung disease market valued at $6B in 2025 expected to grow 8.7% annually through 2036, driven by FDA-approved therapies and emerging pipeline candidates.

Over 30 pharma companies develop 35+ severe asthma drugs with recent approvals validating new mechanisms, signaling major market opportunity and competitive intensity ahead.

Sanofi's lunsekimig met primary endpoints in asthma and nasal polyp trials but failed dermatitis goals, showing favorable safety across all studies.

President Trump's executive order imposes 100% tariffs on imported drugs, exempting 13 companies with MFN agreements and U.S. manufacturing commitments through 2029.

Trump administration preparing 100% tariffs on pharmaceutical companies refusing pricing deals, with major drugmakers already securing three-year reprieves through MFN agreements.

SCYNEXIS completes acquisition of PXL-770 AMPK activator for ADPKD treatment. Deal includes $8M upfront, up to $188M milestones; Phase 2 study planned for late 2026.

Clinical-stage biotech Sitryx Therapeutics will present at four investor conferences in April 2026, highlighting its oral autoimmune and inflammatory disease therapies.

Amgen and GSK join TrumpRx.gov offering up to 80% and 10-55% discounts respectively, expanding the platform to 54 drugs amid Trump administration pricing pressure.

BIO-Europe Spring 2026 in Lisbon expects 3,700+ attendees, 20,000+ meetings, and robust partnering activity as global biopharma industry seeks strategic deals and investment opportunities.

GSK's Arexvy RSV vaccine gains FDA approval for younger high-risk adults aged 18-49, expanding market beyond 60+ population on strong Phase 3b data and £198M Q4 sales.

Shingles vaccine market poised for robust growth through 2036 driven by aging populations, vaccine adoption, and emerging candidates challenging market leader SHINGRIX.

Infanrix vaccines experience robust growth driven by rising birth rates in emerging economies, expanded immunization programs, and increased vaccine manufacturing investments through 2035.

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.

Global antibiotics market to grow from USD 55.60B in 2025 to USD 70.64B by 2031 at 4.07% CAGR, driven by antimicrobial resistance and innovation.